Advertisement

Topics

Isogenica Limited Company Profile

19:32 EDT 20th September 2017 | BioPortfolio

Isogenica was launched in December 2000 by Dr Kevin FitzGerald and Dr Simon Kerry through a £1.8m private equity placement. Isogenica's vision is to become a world leader in the commercial exploitation of molecular evolution technologies.

The Company has a highly innovative, proprietary, in vitro molecular evolution technology called Covalent Display Technology (CDT), which can be used for a wide range of applications including:



the accelerated discovery of peptide, protein and antibody therapeutics;

the development of high affinity ligands for the validation of targets arising from genomics/proteomics studies;

the development of high affinity ligands for diagnostics and medical imaging applications;

the development of high affinity ligands for the production of bioseparations media.

Isogenica intends to generate income from its molecular evolution technologies in three ways:



· through an in-house therapeutic discovery programme;



· though strategic collaborations with partner companies (e.g. for target validation purposes);



· by offering technology licenses to partner companies in discrete application areas

Location

Babraham Hall, Babraham
Cambridge
Cambridgeshire
CB2 4AT
United Kingdom

Contact

Phone: 01223 496722
Fax: 01223 496 721
Email: simon.kerry@isogenica.com


News Articles [21 Associated News Articles listed on BioPortfolio]

Takeda licenses Isogenica's llamdA antibody libraries

Isogenica Ltd. granted Takeda Pharmaceutical Co. Ltd. rights to use its llamdA (llama domain antibody) libraries of synthetic camelid single-domain antibodies (VHH) in its drug discovery efforts.

Isogenica Announces New Licence Agreement with Takeda

Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced a new licensing deal with Takeda Pharmaceutic...

Isogenica Announces Renewal of Licence Agreement by Harpoon Therapeutics

Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced that Harpoon Therapeutics, a preclinical stag...

Isogenica Limited Announces New Licence Agreement With Takeda

  Life Sciences Jobs   ...

Isogenica Limited Announces Renewal Of Licence Agreement By Harpoon Therapeutics

  Life Sciences Jobs   ...

Quotient Limited to Participate in the UBS Global Healthcare Conference

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference

JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [82 Associated Companies listed on BioPortfolio]

Isogenica Limited

Isogenica was launched in December 2000 by Dr Kevin FitzGerald and Dr Simon Kerry through a £1.8m private equity placement. Isogenica's vision is to become a world leader in the commercial exploitat...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "Isogenica Limited" on BioPortfolio

We have published hundreds of Isogenica Limited news stories on BioPortfolio along with dozens of Isogenica Limited Clinical Trials and PubMed Articles about Isogenica Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Isogenica Limited Companies in our database. You can also find out about relevant Isogenica Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record